{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:38:26Z","timestamp":1772044706128,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2000,3]]},"DOI":"10.1023\/a:1007550717526","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T05:04:10Z","timestamp":1040533450000},"page":"299-305","source":"Crossref","is-referenced-by-count":26,"title":["Persistent Inhibition of CYP3A4 by Ketoconazole in Modified Caco-2 Cells"],"prefix":"10.1007","volume":"17","author":[{"given":"Megan A.","family":"Gibbs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Baillie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny D.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent L.","family":"Kunze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Thummel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"223093_CR1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00008571-199410000-00003","volume":"4","author":"J. C. Kolars","year":"1994","unstructured":"J. C. Kolars, K. S. Lown, P. Schmiedlin-Ren, M. Ghosh, C. Fang, S. A. Wrighton, R. M. Merion, and P. B. Watkins. CYP3A gene expression in human gut epithelium. Pharmacogenetics\n4:247-259 (1994).","journal-title":"Pharmacogenetics"},{"key":"223093_CR2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","volume":"283","author":"M. F. Paine","year":"1997","unstructured":"M. F. Paine, M. Khalighi, J. M. Fisher, D. D. Shen, K. L. Kunze, C. L. Marsh, J. D. Perkins, and K. E. Thummel. Characterization of inter-and intra-intestinal differences in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther.\n283:1552-1562 (1997).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"223093_CR3","first-page":"14","volume":"60","author":"M. F. Paine","year":"1996","unstructured":"M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, C. L. Marsh, J. P. McVicar, D. M. Barr, B. S. Gillies, and K. E. Thummel. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther.\n60:14-24 (1996).","journal-title":"Clin. Pharmacol. Ther."},{"key":"223093_CR4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0022-3565(25)22834-8","volume":"271","author":"K. E. Thummel","year":"1994","unstructured":"K. E. Thummel, D. D. Shen, T. D. Podoll, K. L. Kunze, W. F. Trager, P. S. Hartwell, V. A. Raisys, C. L. Marsh, J. P. McVicar, D. M. Barr, J. D. Perkins, and R. L. Carithers Jr. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther.\n271:549-556 (1994).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"223093_CR5","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","volume":"338","author":"J. C. Kolars","year":"1991","unstructured":"J. C. Kolars, W. M. Awni, R.M. Merion, and P. B. Watkins. First-pass metabolism of cyclosporin by the gut. Lancet\n338:1488-1490 (1991).","journal-title":"Lancet"},{"key":"223093_CR6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/clpt.1992.174","volume":"52","author":"D. K. Turgeon","year":"1992","unstructured":"D. K. Turgeon, D. P. Normolle, A. B. Leightman, T. M. Annesley, D. E. Smith, and P. B. Watkins. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin. Pharmacol. Ther.\n52:471-478 (1992).","journal-title":"Clin. Pharmacol. Ther."},{"key":"223093_CR7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0009-9236(95)90032-2","volume":"57","author":"M. P. Ducharme","year":"1995","unstructured":"M. P. Ducharme, L. H. Warbasse, and D. J. Edwards. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther.\n57:485-491 (1995).","journal-title":"Clin. Pharmacol. Ther."},{"key":"223093_CR8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0009-9236(95)90068-3","volume":"58","author":"H. H. T. Kupferschmidt","year":"1995","unstructured":"H. H. T. Kupferschmidt, H. R. Ha, W. H. Ziegler, P. J. Meier, and S. Kr\u00e4henb\u00fchl. Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther.\n58:20-28 (1995).","journal-title":"Clin. Pharmacol. Ther."},{"key":"223093_CR9","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1172\/JCI119439","volume":"99","author":"K. S. Lown","year":"1997","unstructured":"K. S. Lown, D. G. Bailey, R. J. Fontana, S. K. Janardan, C. H. Adair, L. A. Fortlage, M. B. Brown, W. Guo, and P. B. Watkins. Grapefruit juice increases felodipine oral availability in humans by increasing intestinal CYP3A protein expression. J. Clin. Invest.\n99:2545-2553 (1997).","journal-title":"J. Clin. Invest."},{"key":"223093_CR10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0009-9236(95)90067-5","volume":"58","author":"D. Y. Gomez","year":"1995","unstructured":"D. Y. Gomez, V. J. Wacher, S. J. Tomlanovich, M. F. Hebert, and L. Z. Benet. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther.\n58:15-19 (1995).","journal-title":"Clin. Pharmacol. Ther."},{"key":"223093_CR11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jps.2600750504","volume":"75","author":"J. Baxter","year":"1986","unstructured":"J. Baxter, C. Brass, and J. Schentag. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. J. Pharm. Sci.\n75:433-447 (1986).","journal-title":"J. Pharm. Sci."},{"key":"223093_CR12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-198814010-00002","volume":"14","author":"T. Daneshmend","year":"1988","unstructured":"T. Daneshmend, and D. Warnock. Clinical pharmacokinetics of ketoconazole. Clin. Pharmacokinet.\n14:13-34 (1988).","journal-title":"Clin. Pharmacokinet."},{"key":"223093_CR13","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1007\/BF01296501","volume":"37","author":"J. Madsen","year":"1992","unstructured":"J. Madsen. Effects of gender, age, and body mass index on gastro-intestinal transit times. Digest Dis. Sci.\n37:1548-1553 (1992).","journal-title":"Digest Dis. Sci."},{"key":"223093_CR14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1124\/mol.51.5.741","volume":"51","author":"P. Schmiedlin-Ren","year":"1997","unstructured":"P. Schmiedlin-Ren, K. E. Thummel, J. M. Fisher, M. F. Paine, K. S. Lown, and P. B. Watkins. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1\u03b1,25-dihydroxyvitamin D3. Mol. Pharmacol.\n51:741-754 (1997).","journal-title":"Mol. Pharmacol."},{"key":"223093_CR15","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0022-3565(24)38245-X","volume":"289","author":"J. M. Fisher","year":"1999","unstructured":"J. M. Fisher, S. A. Wrighton, P. B. Watkins, P. Schmiedlin-Ren, J. C. Calamia, D. D. Shen, K. L. Kunze, and K. E. Thummel. First-pass midazolam metabolism catalyzed by 1\u03b1,25-dihydroxy Vitamin D3 modified Caco-2 cell monolayers. J. Pharmacol. Exp. Ther.\n289:1134-1142 (1999).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"223093_CR16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0090-9556(24)15274-9","volume":"27","author":"M. A. Gibbs","year":"1999","unstructured":"M. A. Gibbs, K. E. Thummel, D. D. Shen, and K. L. Kunze. Inhibition of CYP3A in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos.\n27:180-187 (1999).","journal-title":"Drug Metab. Dispos."},{"key":"223093_CR17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/j.1875-9114.1984.tb03398.x","volume":"4","author":"J. V. T. yle","year":"1984","unstructured":"J. V. T yle. Ketoconazole: Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy\n4:343-373 (1984).","journal-title":"Pharmacotherapy"},{"key":"223093_CR18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-9236(97)90150-8","volume":"62","author":"L. Floren","year":"1997","unstructured":"L. Floren, I. Bekersky, L. Benet, Q. Mekki, D. Dressler, J. Lee, J. Roberts, and M. Hebert. Tacrolimus oral bioavailability double with coadministration of ketoconazole. Clin. Pharmacol. Ther.\n62:41-49 (1997).","journal-title":"Clin. Pharmacol. Ther."},{"key":"223093_CR19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0022-3565(25)12958-3","volume":"277","author":"J. C. Fleishaker","year":"1996","unstructured":"J. C. Fleishaker, P. G. Pearson, L. C. Wienkers, L. K. Pearson, and G. R. Graves. Biotransformation of tirilazad in humans: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J. Pharmacol. Exp. Ther.\n277:991-998 (1996).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"223093_CR20","first-page":"195","volume-title":"Cytochrome P450: Biochemcistry and Biophysics","author":"E. Antignac","year":"1989","unstructured":"E. Antignac, B. Koch, and J. Narbonne. Interactions of imidazole with purified cytochrome P450: Spectral modifications. In, I. Schuster, (ed), Cytochrome P450: Biochemcistry and Biophysics, Taylor and Francis, New York, 1989, pp. 195-199."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1007550717526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1007550717526\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1007550717526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T07:41:46Z","timestamp":1754034106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1007550717526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["223093"],"URL":"https:\/\/doi.org\/10.1023\/a:1007550717526","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}